SymBio acquires initial Japanese rights to rigerimod for lupus
This article was originally published in Scrip
Executive Summary
SymBio Pharmaceuticals has acquired from Cephalon the exclusive rights to conduct an early clinical programme in Japan for a potential new therapy for systemic lupus erythematosus (SLE).